Eliminación de la hepatitis C en usuarios de drogas inyectadas en México durante la pandemia de COVID-19
Year: 2022
Type: article
Abstract: In 2019, Mexico was one of the first countries in Latin America to commit resources to achieve hepatitis C elimination by 2030.One year after this commitment, the global COVID-19 pandemic diverted attention to address immediate health needs to combat the spread of the disease.As a result, efforts to implement hepatitis C prevention and management programs were indefinitely postponed.Furthermore, populations at high risk of contracting the hepatitis C virus (HCV) and who bear the greatest burden of HCV national epidemic, including people who inject drugs and people who live with human immunodeficiency virus infection, remain exposed to extreme health disparities, which have potentially been exacerbated during the COVID-19 pandemic.In this article, we discuss the potential impact the COVID-19 pandemic has had on HCV elimination efforts in Mexico and the urgent need to resume them, since without these efforts, HCV elimination goals are likely not be achieved in the country by 2030.
Source: Gaceta Médica de México
Language: Spanish
Topic: Hepatitis C virus research
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G342295615, G3789320706, G495691247, G55634203, Optimizing HIV prevention portfolios targeting people who inject drugs using dynamic economic modeling, Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism, G7291770091, G8259150102, G9000124410, Training Program in Substance Use, HIV and Related Infections, San Diego Center for AIDS Research (SD CFAR), University of California Launching Future Leaders in Global Health Research Training Program
OpenAlex ID: W4280640526